Empasiprubart

Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models[1][2].

Product Specifications

CAS Number

[2579031-19-7]

Product Name Alternative

ARGX-117

UNSPSC

12352203

Target

Complement System

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/empasiprubart.html

Purity

99.99

Solubility

10 mM in DMSO

Smiles

[Empasiprubart]

Molecular Weight

(145.74 kDa)

References & Citations

[1]Van de Walle I, et al. ARGX-117, a therapeutic complement inhibiting antibody targeting C2. J Allergy Clin Immunol. 2021 Apr;147 (4) :1420-1429.e7. |[2]Campbell CI, et al. Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model. Brain Commun. 2022 Nov 23;4 (6) :fcac306. |[3]Budding K, et al. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9 (1) :e1107.